Skip to content

Study · Systematic review · 2026

10 results

Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.

Eisa N, Barood O

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists17 Dec 2025

PMID41419187 (opens in a new tab)DOI10.1016/j.eprac.2025.11.018 (opens in a new tab)PepBankPUB-41419187
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials in adults, semaglutide reduced major adverse cardiovascular events by 16% (RR 0.84).

    In plain wordsAcross trials in adults, semaglutide lowered the risk of major heart events by 16%.

    Peptide
    Semaglutide
    Outcome
    DecreaseMajor adverse cardiovascular events
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    0.84 ratio
    semaglutide

    Source sentences

    Summary
    major adverse cardiovascular events reduction (16%, risk ratio [RR]: 0.84, 95% CI: 0.77-0.92)
    2 context sentences
    Summary · context
    Eligible studies included randomized controlled trials in adults (≥18 years) with ≥24-week follow-up comparing semaglutide (≥0.5 mg weekly subcutaneous or ≥7 mg daily oral) versus placebo or active comparators.
    Summary · context
    Thirty-five trials (n = 36 847; mean age 54.2 years; body mass index: 34.8 kg/m2) were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials in adults, semaglutide increased resolution of metabolic dysfunction-associated steatohepatitis (62.9%; RR 1.84).

    In plain wordsAcross trials in adults, fatty liver inflammation cleared up more often with semaglutide than with comparators.

    Peptide
    Semaglutide
    Outcome
    IncreaseResolution of metabolic dysfunction-associated steatohepatitis
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    Resolution rate
    62.9%
    semaglutide
    Risk ratio
    1.84 ratio
    semaglutide

    Source sentences

    Summary
    metabolic dysfunction-associated steatohepatitis resolution (62.9%, RR: 1.84, 95% CI: 1.49-2.27)
    2 context sentences
    Summary · context
    Eligible studies included randomized controlled trials in adults (≥18 years) with ≥24-week follow-up comparing semaglutide (≥0.5 mg weekly subcutaneous or ≥7 mg daily oral) versus placebo or active comparators.
    Summary · context
    Thirty-five trials (n = 36 847; mean age 54.2 years; body mass index: 34.8 kg/m2) were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials in adults, semaglutide reduced composite renal endpoints (HR 0.76).

    In plain wordsAcross trials in adults, semaglutide lowered the risk of serious kidney outcomes compared with comparators.

    Peptide
    Semaglutide
    Outcome
    DecreaseComposite renal endpoints
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.76 ratio
    semaglutide

    Source sentences

    Summary
    renal protection (HR: 0.76, 95% CI: 0.68-0.85)
    2 context sentences
    Summary · context
    Eligible studies included randomized controlled trials in adults (≥18 years) with ≥24-week follow-up comparing semaglutide (≥0.5 mg weekly subcutaneous or ≥7 mg daily oral) versus placebo or active comparators.
    Summary · context
    Thirty-five trials (n = 36 847; mean age 54.2 years; body mass index: 34.8 kg/m2) were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials in adults, semaglutide reduced glycated hemoglobin (-1.52%).

    In plain wordsAcross trials in adults, semaglutide lowered glycated hemoglobin, a measure of long-term blood sugar, by 1.52%.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlycated hemoglobin change
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c change
    −1.52%
    semaglutide

    Source sentences

    Summary
    Semaglutide reduced glycated hemoglobin (-1.52%, 95% confidence interval [CI]: -1.60 to -1.44)
    2 context sentences
    Summary · context
    Eligible studies included randomized controlled trials in adults (≥18 years) with ≥24-week follow-up comparing semaglutide (≥0.5 mg weekly subcutaneous or ≥7 mg daily oral) versus placebo or active comparators.
    Summary · context
    Thirty-five trials (n = 36 847; mean age 54.2 years; body mass index: 34.8 kg/m2) were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials in adults, semaglutide reduced body weight (-12.4 kg).

    In plain wordsAcross trials in adults, semaglutide lowered body weight by about 12 kg.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight change
    −12.4 kg
    semaglutide

    Source sentences

    Summary
    weight (-12.4 kg, 95% CI: -13.0 to -11.8)
    2 context sentences
    Summary · context
    Eligible studies included randomized controlled trials in adults (≥18 years) with ≥24-week follow-up comparing semaglutide (≥0.5 mg weekly subcutaneous or ≥7 mg daily oral) versus placebo or active comparators.
    Summary · context
    Thirty-five trials (n = 36 847; mean age 54.2 years; body mass index: 34.8 kg/m2) were included.
  6. 06HumanSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials in adults, semaglutide improved vascular function, with +87 m walking distance.

    In plain wordsAcross trials in adults, people on semaglutide walked about 87 metres farther.

    Peptide
    Semaglutide
    Outcome
    IncreaseWalking distance (vascular function)
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Walking distance change
    87 m
    semaglutide

    Source sentences

    Summary
    improved vascular function (+87 m walking distance)
    2 context sentences
    Summary · context
    Eligible studies included randomized controlled trials in adults (≥18 years) with ≥24-week follow-up comparing semaglutide (≥0.5 mg weekly subcutaneous or ≥7 mg daily oral) versus placebo or active comparators.
    Summary · context
    Thirty-five trials (n = 36 847; mean age 54.2 years; body mass index: 34.8 kg/m2) were included.
  7. 07HumanSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials in adults, semaglutide produced favorable body composition, with an 87:13 fat-to-lean ratio.

    In plain wordsAcross trials in adults, semaglutide was linked to a favorable body composition, with a fat-to-lean ratio of 87:13.

    Peptide
    Semaglutide
    Outcome
    Not applicableBody composition (fat-to-lean ratio)
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    favorable body composition (87:13 fat-to-lean ratio)
    2 context sentences
    Summary · context
    Eligible studies included randomized controlled trials in adults (≥18 years) with ≥24-week follow-up comparing semaglutide (≥0.5 mg weekly subcutaneous or ≥7 mg daily oral) versus placebo or active comparators.
    Summary · context
    Thirty-five trials (n = 36 847; mean age 54.2 years; body mass index: 34.8 kg/m2) were included.
  8. 08HumanSystematic reviewEfficacy outcome

    In a meta-analysis of randomized trials in adults, semaglutide improved quality of life by +3.8 SF-36 points.

    In plain wordsAcross trials in adults, people on semaglutide reported better quality of life.

    Peptide
    Semaglutide
    Outcome
    IncreaseQuality of life (SF-36)
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    Dose not stated

    Measurements

    SF-36 change
    3.8 points
    semaglutide

    Source sentences

    Summary
    better quality of life (+3.8 SF-36 points)
    2 context sentences
    Summary · context
    Eligible studies included randomized controlled trials in adults (≥18 years) with ≥24-week follow-up comparing semaglutide (≥0.5 mg weekly subcutaneous or ≥7 mg daily oral) versus placebo or active comparators.
    Summary · context
    Thirty-five trials (n = 36 847; mean age 54.2 years; body mass index: 34.8 kg/m2) were included.
  9. 09HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials in adults, semaglutide showed no increase in psychiatric risk.

    In plain wordsAcross trials in adults, semaglutide did not raise psychiatric risk.

    Peptide
    Semaglutide
    Outcome
    No significant changePsychiatric risk
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Outcome group
    Adverse events · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No increase was observed in psychiatric or cancer risk.
    2 context sentences
    Summary · context
    Eligible studies included randomized controlled trials in adults (≥18 years) with ≥24-week follow-up comparing semaglutide (≥0.5 mg weekly subcutaneous or ≥7 mg daily oral) versus placebo or active comparators.
    Summary · context
    Thirty-five trials (n = 36 847; mean age 54.2 years; body mass index: 34.8 kg/m2) were included.
  10. 10HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials in adults, semaglutide showed no increase in cancer risk.

    In plain wordsAcross trials in adults, semaglutide did not raise cancer risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeCancer risk
    Study

    n: not reported in source

    Comparator
    Placebo or active comparators
    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No increase was observed in psychiatric or cancer risk.
    2 context sentences
    Summary · context
    Eligible studies included randomized controlled trials in adults (≥18 years) with ≥24-week follow-up comparing semaglutide (≥0.5 mg weekly subcutaneous or ≥7 mg daily oral) versus placebo or active comparators.
    Summary · context
    Thirty-five trials (n = 36 847; mean age 54.2 years; body mass index: 34.8 kg/m2) were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.